As the largest and most qualified provider of vaccines and antivenom for the country’s public health system, as from 2017, Butantan adopted a strategy to strengthen its position in Brazil and gain a foothold in the world market via collaborations and partnerships, at the same time promoting important adjustments in its industrial park.
All 2019 infrastructure projects have been reviewed to match the short and mid-term strategies to increase the nominal output capacity.
A new Business Unit is in place, dedicated to building partnerships with a view to accelerate the absorption of new technologies and to provide a wider product and services portfolio to meet increasing public health demands.
